BIOSTRATEGIES LC
State University, AR · Biotech · Private
RTB-mediated enzyme delivery technology for rare genetic disease therapeutics, specifically RTB:GALNS fusion protein for MPS-IVA treatment
- Grants
- $27M
- 39 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 4 granted · 15 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2007200920112013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Agriculture · Plant-based Bioproduction Of Chicken IL-12 Adjuvant For Bird Flu Vaccine | $350,000 | |
| Federal grant· 2 of 2 same day | Department of Agriculture · Plant-based Bioproduction Of Chicken IL-12 Adjuvant For Bird Flu Vaccine | $64,000 | |
| Federal grant | Department of Agriculture · Plant Produced Porcine IL-12 Vaccine Adjuvant For Swine Flu And Other Viral Diseases | $90,000 | |
| Federal grant | Department of Agriculture · Plant Produced Porcine IL-12 Vaccine Adjuvant For Swine Flu And Other Viral Diseases | $460,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $185,915 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | $831,740 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | $1,491,165 | |
| Federal grant | Department of Health and Human Services · Phase I · Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme replacement therapy for Sanfilippo A lysosomal rare disease | $659,425 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | $1,366,586 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | $2,438,483 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $1,237,037 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $2,384,044 | |
| Federal grant | Department of Health and Human Services · Phase I · MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving MPS I ERT Efficacy through Lectin-Mediated Delivery | $1,147,007 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease | $1,071,897 | |
| Federal grant | Department of Health and Human Services · Phase I · Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease | $293,232 | |
| Federal grant | Department of Health and Human Services · Phase I · Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease | $293,232 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $1,144,737 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $2,049,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization | $905,262 | |
| Federal grant | Department of Health and Human Services · Phase I · Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS | $390,497 | |
| Federal grant | Department of Health and Human Services · Phase I · Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS | $390,497 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | $1,500,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | $1,500,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases | $295,923 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases | $295,923 | |
| Federal grant | Department of Health and Human Services · Phase II · Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome) | $1,498,067 | |
| Federal grant | Department of Health and Human Services · Phase II · Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme | $1,500,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2468 | PULMOTECT, INC | — | $22M |
| 2469 | New Echota Biotechnology | — | — |
| 2470 | Rocket Pharmaceuticals Ltd. | — | $28M |
| 2471 | BIOSTRATEGIES LC | — | — |
| 2472 | Fulgent Pharma LLC | — | $5.4M |
| 2473 | Kestrel Therapeutics Inc. | — | $21M |
| 2474 | FIBRONOX, L.L.C. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Plant Lectins As Carriers Of Associated Drug Substances Into Animal And Human Cellsapplication
- Method of Co-Expressing a Sulfatase and a Sulfatase Modifying Factor in a Plant or Plant Cellapplication
- Plant Lectins As Carriers Of Associated Drug Substances Into Animal And Human Cellsgranted
- Method Of Co-expressing A Sulfatase And A Sulfatase Modifying Factor In A Plant Or Plant Cellgranted
- Materials and Methods for Therapy of the Musculoskeletal System and Other Tissuesapplication
- Materials And Methods For Mitigating Immune-sensitizationapplication
- Plant Lectins As Carriers Of Associated Drug Substances Into Animal And Human Cellsgranted
- Materials And Methods For Mitigating Immune-sensitizationapplication
- Plant Lectins As Carriers Of Associated Drug Substances Into Animal And Human Cellsgranted
- A Method For Producing A Mammalian SUMF1 Protein By Expressing In A Plantapplication
- Plant Lectins As Carriers Of Associated Drug Substances Into Animal And Human Cellsapplication
- Materials And Methods For Mitigating Immune-sensitizationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.